Allogene Therapeutics, INC 8-K filings

Allogene Therapeutics reported second quarter 2026 financial results and provided a corporate update, highlighting progress in its pivotal ALPHA3 trial for cema-cel and its RESOLUTION trial for ALLO-329.

Allogene Therapeutics has named Dr. Zachary Roberts as its new President and CEO, effective July 1, 2026, succeeding Dr. David Chang.

Allogene Therapeutics terminates its exclusive license agreement with Overland Therapeutics and provides a corporate update with Q1 2026 financial results, highlighting progress in its cema-cel and ALLO-329 clinical trials.

Allogene Therapeutics has priced a public offering of 87.5 million shares of common stock at $2.00 per share to raise $175 million in gross proceeds.

Allogene Therapeutics announced a proposed underwritten public offering of its common stock, suspending sales under its existing at-the-market program.

Allogene Therapeutics announced interim futility analysis from its Phase 2 ALPHA3 trial showing significantly higher MRD negativity rates with cema-cel compared to observation in first-line LBCL.

Allogene Therapeutics announced its fourth quarter and full year 2025 financial results and provided key updates on its pivotal ALPHA3 and RESOLUTION clinical trials.

Allogene Therapeutics announced its third-quarter 2025 financial results and provided updates on its clinical programs, including progress in LBCL, autoimmune disease, and renal cell carcinoma.

Allogene Therapeutics disclosed a patent infringement lawsuit filed against its gene-editing technology licensor, Cellectis, which could impact Allogene's key product candidates.

Allogene Therapeutics announced its second quarter 2025 financial results and provided updates on its pivotal ALPHA3 trial, autoimmune disease program, and solid tumor CAR T therapy.

Allogene Therapeutics, Inc. announced the discontinuation of the ALLO-647 arm in its ALPHA3 study for large B-cell lymphoma due to a Grade 5 adverse event, shifting to a standard lymphodepletion regimen.

Allogene Therapeutics, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all three Class I Directors were re-elected, executive compensation was approved on an advisory basis, and Ernst & Young LLP was ratified as the independent auditor for fiscal year 2025.

Allogene Therapeutics announces its Q1 2025 financial results, highlighting progress in its ALPHA3 trial for LBCL and the RESOLUTION trial for autoimmune diseases, while extending its cash runway into the second half of 2027 through cost realignment.

Allogene Therapeutics announces fourth quarter and full year 2024 financial results, highlighting progress in its AlloCAR T programs and anticipating key data milestones in 2025.

Allogene Therapeutics and Foresight Diagnostics amend their strategic collaboration to develop a companion diagnostic assay in multiple regions, with Allogene funding $37.3 million.

Allogene Therapeutics reports that executive officer Timothy Moore will be leaving the company on February 28, 2025, with severance benefits and a potential consulting agreement.

Allogene Therapeutics has decided to discontinue enrollment in its Phase 1 ALPHA2 clinical trial for cemacabtagene ansegedleucel (cema-cel) in relapsed or refractory chronic lymphocytic leukemia (CLL) due to slow enrollment.

Allogene Therapeutics reported third quarter 2024 financial results and provided a business update, highlighting progress in its allogeneic CAR T cell therapy programs.

Allogene Therapeutics has amended its Code of Business Conduct and Ethics to enhance compliance standards and clarify various policies.

Allogene Therapeutics announced the initiation of a pivotal Phase 2 trial for its lead candidate, cema-cel, and provided a financial update for the second quarter of 2024.

Allogene Therapeutics appointed Annie Yoshiyama as principal accounting officer, replacing Geoffrey Parker in that role, and held its 2024 Annual Meeting of Stockholders.

Allogene Therapeutics has restructured its joint venture with Overland Pharmaceuticals, resulting in a shift in ownership and revised licensing terms for its cell therapy products in specific Asian markets.

Allogene Therapeutics has entered into agreements for a registered direct offering of common stock, expected to generate approximately $110 million in gross proceeds.

Allogene Therapeutics reports Q1 2024 financial results, expands its oncology rights to include all EU member states and the UK, and provides updates on its clinical programs.

Allogene Therapeutics announced its fourth quarter and full year 2023 financial results, along with updates on its clinical programs, including the start of a pivotal trial for its lead candidate.

Allogene Therapeutics will restate its financial statements from 2020 to 2023 due to an accounting error related to its joint venture, Allogene Overland Biopharm.

Allogene Therapeutics has amended its collaboration agreement with Notch Therapeutics, relinquishing rights to several CAR targets while retaining one and an option for another, and securing potential future payments.